By Market News Video Staff, Tuesday, November 16, 12:21 PM ET
Human Genome Sciences (HGSI) shares were halted Tuesday while a Food and Drug Administration advisory panel met to discuss its recommendation on whether to approve the lupus treatment Benlysta, on which Human Genome is partnered with GlaxoSmithKline (NYSE:GSK). The FDA is not required to follow the recommendation of the advisory panel, but it typically does.
Human Genome Sciences is a 4.84% holding of the First Trust NYSE Arca Biotechnology Index Fund (AMEX:FBT), trading lower by 1.1% today. Illumina (NASDAQ:ILMN), at 5.97% of the portfolio, is the top stock, followed by Biogen Idec (NASDAQ:BIIB), at 5.7% of the fund.
The ETF Channel Flexible Growth Investment Portfolio is designed to seek growth for investors — anywhere and everywhere. The key to the program is our portfolio strategy allows us complete flexibility in terms of asset allocation as there are no predetermined guidelines as to the level of stocks, bonds, cash, regions, countries, sectors, commodities, or even asset classes in the portfolio! In short, this is a completely flexible portfolio designed to follow the performance trail wherever it leads us.
This Article's Word Cloud:AMEXAdministrationBIIBBiotechnologyDrugFirstFoodGenomeGlaxoSmithKlineHumanInvestmentNYSEPortfolioSciencesTuesdayadvisoryallowsassetbondsclassescommoditiescompletecompletelycountriesdesignedfollowfollowedgrowthguidelineshaltedinvestorsleadslowerlupuspanelpartneredperformanceportfolioprogramrecommendationsharesshortstockstermstheretreatmentwerewhetherwhilewith
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.